Your SlideShare is downloading. ×
Where are We in the Search for an HIV Vaccine?
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Where are We in the Search for an HIV Vaccine?

247
views

Published on

Workshop organised by Avac, NAM, and AHPN. …

Workshop organised by Avac, NAM, and AHPN.
London 7 November 2013

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
247
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Roger Tatoud, Ph.D UK HIV Vaccine Consortium (UK HVC) Imperial College London 1
  • 2. AHPN, June 2010 AHPN, November 2013 34 33.4 million of people • living with HIV 2.5 2.7 million new • 7.0 infections • 9.5 million of people in 53%need of treatment • 42% had access to 1.7 treatment • 2.0 million AIDSrelated death 0 • • • • Cure Vaccine Microbicide Changes in behaviour or technology that works 100% of the time 2
  • 3. 3
  • 4. 4
  • 5. 1 Basic research Prototype Discovery & Design Pre-clinical Development 3 Early clinical trials (I/II) Late clinical trials (III/IV) Regulatory approval Marketing Post marketing compliance Patient 32 years and counting 1-2 years 2 Product Manufactur e Time taken from discovery of the pathogen to existence of the vaccine: 2-5 years 1-2 years Product Manufactur e 3-10 years • Typhoid: 105 years • Whooping cough: 89 years • Polio: 47 years • Measles: 42 years HIV: 35-55 years? 5
  • 6. Commercialisation Industry Acad. 1 Partners Case for support IP Contract Tox Funding Product GMP Lab Dissemination Trial ICH-GCP QP PPI Stats CTU NHS Phase II? 6
  • 7. 2 http://www.vaccineenterprise.org/Benchtoclinic 7
  • 8. 3 http://www.ct-toolkit.ac.uk/ 8
  • 9. Structur e& function Cat “HIV” Basic research Prototype Discovery & Design STEP & HVTN505 Louis Picker CMV UK HVC Spoke 003 Pre-clinical Development RV144 (Thai Trial) Early clinical trials (I/II) 32 years and counting Late clinical trials (III/IV) CAPRISA Regulatory approval Marketing Post marketing compliance Patient PrEP (USA) iPrEX 1-2 years Product Manufactur e 2-5 years 1-2 years Product Manufactur e 3-10 years 9
  • 10. • Long, complex, slow process • A range of expertise that are not always at hand • Collaborations • Trials & Errors • Reasons to be hopeful • Beware of the hype • Involving the public 10